Neuronal Apoptosis and Motor Deficits in Mice with Genetic Inhibition of GSK-3 Are Fas-Dependent

Raquel Gómez-Sintes1,2, José J. Lucas1,2*

1Centro de Biología Molecular “Severo Ochoa” (CBM"SO"), CSIC/UAM, Madrid, Spain, 2Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain

Abstract

Glycogen synthase kinase-3 (GSK-3) inhibitors have been postulated as useful therapeutic tools for the treatment of chronic neurodegenerative and neuropsychiatric diseases. Nevertheless the clinical use of these inhibitors has been limited by their common side effects. Lithium, a non-selective GSK-3 inhibitor has been classically administered to treat bipolar patients but its prescription is decreasing due to its frequent side effects such as hand tremor. This toxicity seems to be higher in the elderly and a clinical trial with lithium for Alzheimer’s disease was stopped due to high rate of discontinuation. We have previously described a mechanism for the adverse effects of chronic lithium that involves neuronal apoptosis via Fas signaling. As lithium inhibits many other enzymatic activities such as inositol monophosphatase and histone deacetylase, we aim to genetically test whether GSK-3 inhibition induces those adverse effects through Fas receptor. For this purpose we took advantage of a transgenic mouse line with decreased GSK-3 activity (Tet/DN-GSK-3 mice) that shows increased rate of neuronal apoptosis as well as motor deficits and brought it to a Fas deficient background (lpr mice). We found that apoptosis induced by GSK-3 inhibition was absent in Fas deficient background. Interestingly, motor deficits were also absent in Fas deficient Tet/DN-GSK-3 mice. These results demonstrate that Fas signaling contributes to the neurological toxicity of GSK-3 inhibition and suggest that a combination of GSK-3 inhibitors with blockers of Fas signaling could help to improve the application of GSK-3 inhibitors to clinics.

Introduction

GSK-3 is involved in many cellular signaling pathways such as the insulin/PI3K or the Wnt pathways and participates in a high number of functions such as metabolism, cell proliferation, cell fate, survival and apoptosis [1,2,3,4,5]. Besides, it also plays a key role in many neuronal specific functions like long term potentiation (LTP) and depression (LTD) of synaptic activity [6,7]. Dysregulation of GSK-3 has been postulated to participate in the etiology of neurodegenerative or neurodegenerative diseases: bipolar disorder [8,9,10], schizophrenia [9,11], Alzheimer’s disease (AD) [3,12,13] or Huntington’s disease [14,15,16] and of non-CNS diseases: type 2 diabetes [17] or cancer [18]. Consequently, GSK-3 inhibitors have been postulated as a promising therapeutic tool [19,20]. Lithium inhibits GSK-3 [21,22,23] and this has been postulated to contribute to its therapeutic efficacy [8,9,10] but also to its neurological toxicity [24]. Together, this lithium’s adverse effects [25] and those of GSK-3 genetic inhibition [26,27] warn about possible limitations of GSK-3 inhibitor based therapies. Understanding of the mechanism of this toxicity and of how to counteract it may be a key step for successful therapeutic use of GSK-3 inhibitors.

GSK-3 is implicated in apoptosis but its modulatory effect can be different depending on the specific apoptotic pathway involved: intrinsic (type I) that involves release of cytochrome c and disintegration of mitochondria and extrinsic (type II) apoptosis that occurs upon the activation of death receptors, specifically the TNF receptor family including Fas and TRAIL [28]. Consequently, lithium and other GSK-3 inhibitors are protective towards many apoptotic stimuli that affect mitochondrial integrity but increase apoptosis triggered by TNF [26,29] or Fas [30]. Conceivably, this may have significant implications on the therapeutic potential of GSK-3 inhibitors.

Mice with conditional expression of a dominant negative form of GSK-3 (Tet/DN-GSK-3 mice) [27] are a useful tool to explore the neurological consequences of chronically decreasing GSK-3 activity in the brain [24]. Tet/DN-GSK-3 mice display increased rate of neuronal apoptosis and impaired motor coordination [27] that might relate to the frequent neurological motor side effects, such as hand tremor, experienced by lithium-treated patients [25]. Interestingly, wild type mice chronically treated with lithium also show increased rate of neuronal apoptosis and a deficit in motor coordination that have been reported to occur through a mechanism involving Fas, as they are absent in Fas-deficient mice (lpr mice) [24]. Since lithium inhibits other enzymes like inositol-monophosphatase or histone-deacetylase [31], it cannot be ascertained that this toxicity mechanism is due to GSK-3 inhibition. Here we test if apoptosis and related behavioral consequences due to decreased GSK-3 activity are Fas dependent.
A. Breeding protocol

| Breeding design | F₀ | F₁ | F₂ |
|-----------------|----|----|----|
| lpr/lpr x Tet/DN-GSK-3 | lpr/+ Tet/DN-GSK-3 (25%) | lpr/+ (100%) |

B. Identification of the different genotypes by PCR to detect the CamKII-tTA and the DN-GSK-3 transgenes and the presence of the lpr mutation. Line 1: wt; line 2: Tet/DN-GSK-3; line 3: lpr/+; line 4: lpr/+; Tet/DN-GSK-3; line 5: lpr/lpr; line 6: lpr/lpr; Tet/DN-GSK-3.

C. Body weight of GSK-3 Inhibition Toxicity is Fas-Dependent
Materials and Methods

Animals

Tet/DN-GSK-3 mice in a C57/BL6J background were generated as described previously [27]. Fas-deficient lpr mice (C57/BL6J background) were obtained from Jackson laboratories (B6.MRL-Faslpr/J, stock number: 000482). All mice were housed at the Centro de Biología Molecular “Severo Ochoa” animal facility. Mice were housed four per cage with food and water available ad libitum and maintained in a temperature-controlled environment on a 12/12 h light-dark cycle with light onset at 07:00 h. For behavioral analysis, mice were tested at the age of 2.5–3 months and they were sacrificed upon completion of the battery of tests. For histological studies only male mice were used. For behavioral studies males and females were used indistinctly. Statistical analysis as genotype x treatment interaction was evaluated by two way-ANOVA to rule out any effect of sex. All behavioral studies were performed during light phase.

Ethics Statement

Animal housing and maintenance protocols followed the guidelines of Council of Europe Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. Animal experiments were performed under protocols (P15/P16/P18/P22) approved by the Centro de Biología Molecular Severo Ochoa Ethics Statement of Council of Europe Convention ETS123, recently revised as indicated in the Directive 86/609/EEC. Animal experiments were performed under protocols (P15/P16/P18/P22) approved by the Centro de Biología Molecular Severo Ochoa Ethical Review Committee.

PCR

Mice were genotyped by using the following primers:

For detection of the CamKII-tTA (tTA) transgene: primer tTA-C (5’-ACTAAGTCATCGGATGGAGC-3’) and primer tTA-F (5’-GGAATCTGCATAGGCGTCGG-3’) that amplify a 592 bp fragment. For detection of the DN-GSK-3 (tetO-R4) transgene: primer GSK-3A (5’-CAATGGCATGTCATGATGAGC-3’) and primer GSK-3B (5’-TAATCGCGCAGTGCACGGGTGTG) that yield a 179 bp band from the wild type allele and a 217 bp band from the mutant allele.

Western Blot Analysis

Mice were sacrificed using CO2 and brains immediately removed and dissected on an ice-cold plate. Whole extracts were prepared by homogenizing the brain areas from right hemisphere in ice-cold extraction buffer consisting of 20 mM HEPES pH 7.4, 100 mM NaCl, 20 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 1 µM okadaic acid, 5 mM sodium pyrophosphate, 30 mM β-glycerophosphate, 5 mM EDTA, and protease inhibitors (2 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml pepstatin). Samples were homogenized and centrifuged at 15000 g for 20 min at 4°C. The resulting supernatant was collected, and protein content determined by Bradford assay. Fifteen micrograms of total protein were electrophoresed on 10% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane (Schleicher and Schuell). The experiments were performed using the following primary antibodies: anti-β-gal (Promega, 1:2000) and anti-β-actin (Sigma, 1:5000). The membranes were incubated with antibody overnight at 4°C in non-fat dried milk. Secondary antibodies used were polyclonal rabbit anti-mouse immunoglobulins/HRP (DAKO Cytomation) (1:2000) and ECL detection reagents (Perkin Elmer) were used for immunodetection.

Immunofluorescence and Immunohistochemistry

Left hemispheres were processed for histology placed in 4% paraformaldehyde in Sorenson’s phosphate buffer (PFA) overnight, washed in PBS and then immersed in 30% sucrose in PBS for 72 hr. Once cryoprotected, the samples were included in OCT compound (Sakura Finetek Europe) frozen and stored at −80°C until use. 30 µm sagittal sections were cut on a CM 1950 Ag Protect freezing microtome (Leica) and collected and stored free

| Table 1. Genotype frequencies. |
|--------------------------------|
| Nomenclature                  |
| wt                            |
| tTAtetO-R4                    |
| Tet/DN-GSK-3                 |
| lpr/+                        |
| lpr/;tTA                     |
| lpr/+;tetO-R4                |
| lpr/;Tet/DN-GSK-3            |
| Npr/lpr/;Tet/DN-GSK-3        |
| lpr/;lpr/;tetO-R4            |
| lpr/;lpr/;Tet/DN-GSK-3       |
| Distribution/frequencies      |
| N                            |
| 28                            |
| 32                            |
| 20                            |
| 21                            |
| 67                            |
| 37                            |
| 34                            |
| 37                            |
| 27                            |
| 21                            |
| 13                            |
| 10                            |
| Expected frequencies          |
| 6.25                          |
| 6.25                          |
| 6.25                          |
| 12.5                          |
| 12.5                          |
| 12.5                          |
| 12.5                          |
| 6.25                          |
| 6.25                          |
| 6.25                          |
| Observed frequencies          |
| 8.07                          |
| 9.22                          |
| 5.76                          |
| 6.05                          |
| 19.31                         |
| 10.66                         |
| 9.8                           |
| 10.66                         |
| 7.78                          |
| 6.05                          |
| 3.75                          |
| 2.88                          |

GSK-3 Inhibition Toxicity is Fas-Dependent

All resulting genotypes was measured at the age of 2.5 months. One-way ANOVA test followed by Bonferroni post-hoc test was applied to determine the level of significance. The number of analyzed animals is indicated in the graph. Only lpr/lpr mice were significantly different than wt mice (* p=0.05). doi:10.1371/journal.pone.0070952.t001

PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e70952
Corresponds to 10\(^{c}\) caspase-3, NeuN and dapi counterstaining. Scale bar in left panel corresponds to 50 \(\mu m\). Double labeling immunofluorescence with anti-cleaved caspase-3 (red) and NeuN (green) antibodies. Right panel shows a merged image of the immunostaining for the two markers. Scale bar in left panel corresponds to 20 \(\mu m\).

Then, the total number of positive cells was extrapolated for the whole brain structure. For quantification, one every four serial 30 \(\mu m\) planes of the Paxinos and Franklin mouse brain atlas [32]. For quantification of cleaved-caspase-3 immunohistochemistry and TUNEL was performed following a one way-ANOVA test followed by a LSD post-hoc test. * for wt vs. Tet/DN-GSK-3; # for Tet/DN-GSK-3 vs. lpr+/+Tet/DN-GSK-3 and lpr/lpr/Tet/DN-GSK-3 mice.

![D. Quantification of caspase-3 positive cells in cortex (Cx), striatum (St), thalamus (Thal) and cerebellum (Cb) of wt, Tet/DN-GSK-3, lpr+/+, lpr+/+Tet/DN-GSK-3, lpr/lpr and lpr/lpr/Tet/DN-GSK-3 mice (4 male mice per genotype).](Image 58x231 to 275x730)

**Figure 2. Analysis of apoptotic levels in experimental mice.** A. Double labeling immunofluorescence with anti-cleaved caspase-3 (red) and \(\beta\)-gal (green) antibodies. Scale bar in left panel corresponds to 20 \(\mu m\). B. Double labeling immunofluorescence with anti-cleaved caspase-3 (red) and NeuN (green) antibodies. Right panel shows a merged image of caspase-3, NeuN and dapi counterstaining. Scale bar in left panel corresponds to 10 \(\mu m\). C. Immunohistochemistry with anti-cleaved caspase-3 antibody. Left panels correspond to Cx (upper) and St (lower) of wt/Tet/DN-GSK-3. Right panels correspond to Cx (upper) and St (lower) of lpr/lpr/Tet/DN-GSK-3. Scale bar in upper left panel corresponds to 50 \(\mu m\). D. Quantification of caspase-3 positive cells in cortex (Cx), striatum (St), thalamus (Thal) and cerebellum (Cb) of wt, Tet/DN-GSK-3, lpr+/+, lpr+/+Tet/DN-GSK-3, lpr/lpr and lpr/lpr/Tet/DN-GSK-3 mice (4 male mice per genotype). For quantification, one every four serial 30 \(\mu m\)-sagittal sections were selected for staining between the 3.00 mm and 0.72 mm planes of the Paxinos and Franklin mouse brain atlas [32]. Then, the total number of positive cells was extrapolated for the whole structure.

E. TUNEL staining. Low magnification pictures were captured at 20\(\times\), insets were taken at 40\(\times\). Representative images correspond to St of Tet/DN-GSK-3 (left panel) and lpr/lpr/Tet/DN-GSK-3 (right panel). Scale bar corresponds to 50 \(\mu m\). F. Quantification of TUNEL positive cells in cortex (Cx), striatum (St), thalamus (Thal) and cerebellum (Cb) of wt, Tet/DN-GSK-3, lpr+/+, lpr+/+Tet/DN-GSK-3, lpr/lpr and lpr/lpr/Tet/DN-GSK-3 mice. Quantification was performed as for Caspase-3 quantification. The number of animals included in this analysis is 4 male animals per genotype. Data are presented as the mean \(\pm\) s.e.m. number of positive cells per 30 \(\mu m\) section for each structure. Statistical analysis of cleaved caspase-3 immunohistochemistry and TUNEL was performed floating in glycol containing buffer (30% glycerol, 30% ethylene glycol in 0.02 M phosphate buffer) at \(-20^\circ\)C.

For immunofluorescence, 30 \(\mu m\) sagittal brain sections were pretreated with 0.1% Triton X-100 for 15 min, 1 M Glycine for 30 min, and blocking solution (1% BSA and 0.1% Triton X-100) for 1 hour. Sections were then incubated overnight at 4\(^\circ\)C with primary antibodies in blocking solution at the following concentrations: cleaved-caspase-3 (Cell Signaling Technology, MA) (1:50), \(\beta\)-gal (Promega) 1:2000 and NeuN (Chemicon) (1:100). The following day, sections were washed in PBS. Then sections were incubated with donkey anti-rabbit Alexa 555 (Invitrogen) (1:500), donkey anti-mouse Alexa 488 (Invitrogen) (1:1000) and goat anti-mouse Alexa 488 (Invitrogen) (1:1000) secondary antibodies for 1 hour. Finally, nuclei were counterstained with DAPI (1:5000, Calbiochem). Sections were mounted on glass slides, coverslipped with Fluorsave (Calbiochem) and maintained at 4\(^\circ\)C.

Colocalization of markers was identified by taking successive Alexa 555 and Alexa 488 fluorescent images using a Laser Confocal LSM710 camera (Zeiss) coupled to an inverted microscope AxioObserver (Zeiss).

For immunohistochemistry, brain sections were pretreated for 30 min in 1% \(\text{H}_2\text{O}_2\)/PBS followed by 1 h with 1% BSA, 5% FBS and 0.2% Triton X-100 and incubated overnight at 4\(^\circ\)C with \(\beta\)-gal (ICN Biomed.-Cappel, 1:2000) or cleaved-caspase-3 (Cell Signaling, 1:50) primary antibodies. Finally, brain sections were incubated in avidin-biotin complex using the Elite Vectastain kit (Vector Laboratories). Chromogen reactions were performed with diaminobenzidine (SIGMAFAST™ DAB, Sigma) for 10 min. Sections were mounted on glass slides and coverslipped with Fluorosave (Calbiochem). For quantification of cleaved-caspase-3 immunostainings, four male mice per genotype were processed as follows: one every four serial 30 \(\mu m\)-sagittal sections were selected for staining between the 3.00 mm and 0.72 mm planes of the Paxinos and Franklin mouse brain atlas [32]. Round-shape (5–10 \(\mu m\) in diameter) positive cells were quantified with the “Analyze particles” tool of Image J. All analyses were performed blind and results were presented as the estimate of total positive cells in the whole brain structure.

**TUNEL Assay**

Sections were processed according to the In Situ Cell Death Detection Kit protocol (POD, Roche). Quantification was performed on 4 male mice per genotype by staining one every four serial 30 \(\mu m\)-sagittal sections spanning from the 3.00 mm to the 0.72 mm planes of the Paxinos and Franklin mouse brain atlas [32]. Round-shape (5–10 \(\mu m\) in diameter) positive cells were quantified with the “Analyze particles” tool of Image J. All analyses were performed blind and results were presented as the...
Figure 3. Motor deficits in Tet/DN-GSK-3 mice are Fas dependent. A–D. Analysis of gait parameters by using the DigiGait apparatus. Analysis of swing duration (A), stride length variability (B), paw angle variability (C) and paw area variability (D) of experimental mice (wt, n = 13; Tet/DN-GSK-3, n = 12; lpr/+, n = 21; lpr/++;Tet/DN-GSK-3, n = 21; lpr/lpr, n = 14 and lpr/lpr;Tet/DN-GSK-3, n = 8). Statistical analysis of swing duration, stride length
variability and paw angle variability was performed by applying one way-ANOVA test followed by a LSD post-hoc test. Statistical analysis of paw area variability was performed using Kruskal-Wallis test for no parametric distribution of data. Then paired genotypes analysis was performed following a Mann-Whitney U-test and Bonferroni correction was applied. * p < 0.05; ** p < 0.01; *** p < 0.001; * for wt vs. Tet/DN-GSK-3; ** for Tet/DN-GSK-3 vs. lpr/+;Tet/DN-GSK-3 and lpr/+;Tet/DN-GSK-3 mice, E-F. Analysis of motor coordination. E. Time to descend in vertical pole test. (wt, n = 16; Tet/DN-GSK-3, n = 18; lpr/+, n = 28; lpr/+/Tet/DN-GSK-3, n = 23; lpr/lpr, n = 16 and lpr/lpr;Tet/DN-GSK-3, n = 10). Data are presented as the mean ± s.e.m. time to descend the pole. Statistical analysis was performed applying a one way-ANOVA test following a Mann-Whitney U-test. *, p < 0.05. F. Performance in the third and fourth accelerating trials represented as mean ± s.e.m. time on rod (wt, n = 16; Tet/DN-GSK-3, n = 19; lpr/+, n = 28; lpr/+;Tet/DN-GSK-3, n = 25; lpr/lpr, n = 16 and lpr/lpr;Tet/DN-GSK-3, n = 10). Statistical analysis was performed using Kruskal-Wallis analysis for no parametric distribution of data. Then paired genotypes analysis was performed following a Mann-Whitney U-test.

doi:10.1371/journal.pone.0070952.g003
repressible manner (Tet/DN-GSK-3 mice) were generated as previously described [27] by combining mice expressing TTA under CamKIIβ promoter (TIA mice) with mice carrying myc-Ki5R-GSK-3 and β-Gal sequences fused to a bidirectional tetO promoter (tetO-R4 mice). Fas-deficient mice (lpr/lpr mice) are naturally deficient in Fas receptor [35]. Double transgenic Tet/ DN-GSK-3 mice (that carry both the TTA-CamKIIα transgene, and the TetO-R4 transgene) were then combined with lpr/lpr mice as shown in Fig. 1A. Resulting lpr/+;Tet/DN-GSK-3 (F1) were then bred with lpr/+ (F1) to obtain the six experimental genotypes out of the twelve possible ones (Table 1). For identification of genotypes, three different PCR reactions were performed to detect the CamKIIα-TTA construct, the GSK-3 construct and the lpr mutation (Fig. 1B). To verify expression of the transgene, western blot and immunohistochemistry of the β-gal reporter were also performed (Fig. 1B). Analysis of the frequencies by means of a chi-square test revealed that all genotypes adjusted to the expected Mendelian distribution (Table 1) and they displayed no overt phenotype. They also displayed body weight similar to that of their control wild type (wt) littermates (Fig. 1C) except for lpr/lpr mice that were bigger than wild type as previously reported [36]. One-way ANOVA test (p = 0.026) followed by Bonferroni post-hoc test was applied to determine the level of significance and when males and females were tested separately, a similar effect was found for lpr/lpr mice. However, this difference was not evident in lpr/+ mice harbouring any of the Tet/DN-GSK-3 transgenes. For further biochemical, histological and behavioral analysis only wt, Tet/DN-GSK-3, lpr/+ , lpr/+;Tet/DN-GSK-3, lpr/lpr and lpr/lpr;Tet/DN-GSK-3 mice were used and they were analyzed at the age of 2.5–3 months.

Absence of Apoptosis in Cortex and Striatum of Fas Deficient-Tet/DN-GSK-3

For the analysis of apoptosis, immunofluorescence and immunohistochemistry against cleaved (activated) caspase-3 and TUNEL staining were performed in the six experimental groups of mice at the age of 2.5–3 months (Fig. 2). TUNEL is a common method for detecting DNA fragmentation that results from apoptotic signaling cascades and caspase 3 is one the major caspases activated during the execution phase of apoptosis. First, to verify that the cells undergoing apoptosis express the transgene, we performed double immunofluorescence for caspase-3 and the reporter β-gal (Fig. 2A). As described in our previous report [27], double immunofluorescence with caspase-3 and NeuN (neuronal marker) antibodies revealed an increased rate of apoptosis in Tet/DN-GSK-3 mice respect to wild type mice with the majority of apoptotic cells being neurons (Fig. 2B). For a more precise quantification and comparison among the experimental groups with varying lpr genotypes, immunohistochemistry of cleaved caspase-3 was performed (Fig. 2C). Counting of positive caspase-3 cells confirmed the previously reported increased rate of apoptosis in cortex (Cx) and striatum (St) of Tet/DN-GSK-3 mice respect to their corresponding control wt littermates (wt vs. Tet/DN-GSK-3: 334.24 ± 33.61 vs. 578.81 ± 111.68 positive cells in Cx, p = 0.023; 546.32 ± 66.75 vs. 728.70 ± 21.47 positive cells in St, p = 0.01) (Fig. 2C–D). As expected, no effect in the number of caspase-3 positive cells was detected in brain regions that do not express the DN-GSK-3 transgene (TetO-R4 transgene) such as the thalamus or the cerebellum. Interestingly, levels of cortical and striatal apoptosis in Fas-deficient-Tet/DN-GSK-3 mice, either lpr/+;Tet/DN-GSK-3 or lpr/lpr;Tet/DN-GSK-3, were similar to control littermates (Tet/DN-GSK-3 vs. lpr/+;Tet/DN-GSK-3: p = 0.023 in Cx, p = 0.001 in St; Tet/DN-GSK-3 vs. lpr/lpr;Tet/DN-GSK-3: p = 0.062 in Cx, p < 0.000 in St). Therefore indicating that apoptosis resulting after sustained inhibition of GSK-3 in striatum and cortex is Fas dependent. Equivalent results were obtained when apoptosis was analyzed by TUNEL method (wt vs. Tet/DN-GSK-3: p = 0.007 in Cx, p = 0.01 in St; Tet/DN-GSK-3 vs. lpr/+;Tet/DN-GSK-3: p = 0.004 in Cx, p = 0.005 in St; Tet/DN-GSK-3 vs. lpr/lpr;Tet/DN-GSK-3: p = 0.007 in Cx, p = 0.005 in St), (Fig. 2E–F, statistical analysis of cleaved caspase-3 immunohistochemistry and TUNEL was performed following a one way ANOVA test followed by a LSD post-hoc test). Furthermore, since the absence of DN-GSK-3 mediated apoptosis is not only seen in homozygous lpr/lpr background but also in the heterozygous lpr/+ background, just a partial attenuation of Fas-dependent signaling is sufficient to preclude the effect of DN-GSK-3 on apoptosis induction.

Absence of Motor Deficits in Tet/DN-GSK-3 Mice in lpr Background

Increased apoptosis in Tet/DN-GSK-3 is more prominent in striatum and cortex which are part of the basal ganglia circuit, involved in motor control. Accordingly, Tet/DN-GSK-3 mice have been reported to show deficits in motor tasks like the vertical pole and the footprint tests [27]. Since we have found no evidence of increased neuronal death in striatum and cortex of Tet/DN-GSK-3 mice with Fas deficiency (lpr/+ or lpr/lpr;Tet/DN-GSK-3), we wondered whether motor deficits observed in Tet/DN-GSK-3 mice would also be absent in Fas-deficient Tet/DN-GSK-3 mice. To that end, the six experimental groups of mice were subjected to several behavioral tests that detect potential deficiencies in motor tasks. First we performed DigiGait test, which measures footprint pattern and other parameters of walking regularity (Fig. 3A–D). In good agreement with our previous report [27], Tet/DN-GSK-3 mice subjected to analysis of DigiGait parameters showed multiple gait abnormalities such as increased swing duration (ANOVA, p = 0.006, F = 3.374; Fig. 3A), increased variability in stride length (ANOVA, p = 0.043, F = 2.342; Fig. 3B), increased paw angle variability (ANOVA, p = 0.000, F = 10.306; Fig. 3C) and increased paw area variability (Kruskal-Wallis, p = 0.000; Fig. 3D) as compared to wt mice. Interestingly, lpr/+;Tet/DN-GSK-3 and lpr/lpr;Tet/DN-GSK-3 showed no abnormalities compared with their respective controls. Statistical analysis of swing duration, stride length variability and paw angle variability was performed by applying one way ANOVA test followed by a LSD post-hoc test while analysis of paw area variability was performed using Kruskal-Wallis test for no parametric distribution of data. Then paired genotypes analysis was performed following a Mann-Whitney U-test and Bonferroni correction was applied. In summary, these results indicate that the increased variability in walking regularity found in Tet/DN-GSK-3 mice is reduced in Fas-deficient backgrounds.

We then performed tests of striatal-dependent motor coordination like the vertical pole and the rotarod tests (Fig. 3E–F). In good agreement with the above shown results, we found significantly increased time to descend the vertical pole for Tet/DN-GSK-3 mice with respect to their control wt littermates (wt vs. Tet/DN-GSK-3: 17.2 ± 2.2s vs. 10.0 ± 0.8s, ANOVA: p = 0.036, F = 2.485). Interestingly, the difference was smaller and not significant between lpr/+;Tet/DN-GSK-3 (12 ± 1.6s) or lpr/lpr;Tet/DN-GSK-3 (12 ± 1.6s) and their respective controls (Fig. 3E). Statistical analysis was performed applying a one way ANOVA test followed by a LSD post-hoc test. The accelerating rotarod is another test that detects striatal dependent deficits in motor coordination. This test measures the time spent by the mouse on a rotating cylinder (rod) as the speed of rotation is accelerating from 4 to 40 r.p.m. Results of rotarod test were represented as average of third and fourth
trials (Fig. 3F). Despite a tendency to decreased time on rod of Tet/DN-GSK3 mice (wt vs. Tet/DN-GSK-3: 225±8.26 vs. 199±15.1, p = 0.101 in Kruskal-Wallis analysis followed by Mann-Whitney U-test), no significant difference was observed for any group. Finally, to verify that these animals do not show impairment in general locomotive behavior, they were subjected to open field test (Fig. S1) and several parameters as inactivity time (p = 0.209, F = 1.277; Fig. S1A), horizontal activity (p = 0.116, F = 1.376; Fig. S1B), vertical activity (p = 0.064, F = 2.511; Fig. S1C), jump time (p = 0.789; Fig. S1D), stereotypic movements (p = 0.0271, F = 1.32; Fig. S1E) or average velocity (p = 0.098, F = 1.982; Fig. S1F), were measured and no differences among genotypes were found. Statistical analysis was performed applying a one way-ANOVA test except for jump time for that a Kruskal-Wallis test was applied.

**Discussion**

By combining conditional transgenic mice with neuronal expression of a dominant negative form of GSK-3 (Tet/DN-GSK-3 mice) and lpr mice, we have generated mice with sustained inhibition of GSK-3 in a Fas-deficient background for analysis of apoptosis in brain and for behavioral characterization of their ability to carry out motor tasks. Unlike Tet/DN-GSK-3 mice that show increased apoptosis in cortex and striatum [27], lpr/lpr;Tet/DN-GSK-3 mice showed levels of neuronal apoptosis similar to those found in wild type mice. In addition, analysis of motor coordination in tests of walking regularity, in the vertical pole test and in the rotarod test revealed that the motor deficits previously reported in Tet/DN-GSK-3 mice [27] were no longer evident when genetic inhibition of GSK-3 occurs in a Fas-deficient background.

Lithium prescription to bipolar disorder patients has decreased in the last years due to its common side effects [37,38]. Understanding the molecular mechanism by which lithium exerts its neurotoxicity may lead to strategies to overcome its side-effects. In this regard, inhibition of GSK-3 by lithium has been postulated to contribute not only to its therapeutic efficacy [8,9,10] but also to its neurotoxicity [24]. Since increased GSK-3 activity is believed to contribute to the etiology of other pathologies such as AD, lithium has been postulated as a possible therapy for AD [19]. However, despite potential benefits of lithium for amnestic minimal cognitive impairment in a recent trial [39], clinical trials for AD have been hampered by high rates of discontinuation due to lithium’s adverse effects that is even more prominent in the elderly [40]. Therefore, toxicity of lithium therapy is a problem that extends beyond mood disorders. Regarding the molecular basis of lithium toxicity, we have recently reported a mechanism for the neurotoxicity of chronic lithium in mice that is dependent on Fas signaling [24]. As mentioned, lithium also inhibits other enzymatic activities such as inositol monophosphatase and histone deacetylase [31]. Although this study does not provide direct evidence that decreasing Fas would decrease toxicity associated with lithium treatment, the results reported here demonstrate that neuronal apoptosis and motor deficits caused by sustained GSK-3 inhibition are Fas dependent. It is therefore conceivable that Fas signaling modulating drugs could be used in the future to improve clinical use of lithium not only for bipolar disorder but also for AD. Besides, more selective GSK-3 inhibitors are currently under development [19,41], and, similar to lithium, they are known to attenuate neuronal loss in AD animal models with increased GSK3 activity (such β-Amyloid infusion) but also to induce neuronal apoptosis when administered alone to wild type animals without any GSK-3 increasing stimulus [42]. Therefore, modulation of Fas signaling might contribute to the successful application of selective GSK-3 inhibitors to clinics in general.

It is worth noting that factors that attenuate Fas signaling have been suggested per se as a potential avenue for therapeutic intervention for AD [43] since increased levels of Fas protein have been reported in the brain and cerebrospinal fluid of AD patients [44,45] and the Fas gene is located in the 10q24.1 region showing linkage to late onset AD [46,47] with polymorphisms in Fas having shown association with AD progression [48,49]. What would increase the chances of success of a combination of GSK-3 inhibitors and Fas signaling-blockers for AD.

Apart from the mentioned Fas-dependent mechanism for lithium- or genetic GSK-3 inhibition-induced apoptosis there is another reported mechanism by which decreased GSK-3 activity could contribute to exacerbated apoptosis through the extrinsic pathway [50]. More precisely, GSK-3 has been reported to act at an intracellular juxtamembrane location in association with DDX3, the cellular inhibitor of apoptosis protein-1 (cIAP-1) and any of the death receptors to form an antiapoptotic complex. When GSK-3 activity is blocked, stimulation of death receptor potentiates caspase-3 activation [50]. Therefore and in regard to the other above mentioned mechanisms requiring Fas activation, both mechanisms converge in the activation of a death receptor. As in our present study we have blocked apoptosis at the level of Fas (by using Fas-deficient mice), we cannot conclude if stimulation of the receptor or disassembly of the antiapoptotic complex, is predominant. Further experiments specifically aiming blockade of Fas signaling upstream or at the inhibitory complex would be needed to elucidate the contribution of both proposed mechanisms to apoptosis.

One interesting feature of the results reported here is that heterozygous lpr modification of Fas is sufficient to correct both the apoptotic and the motor phenotypes of Tet/DN-GSK-3 mice. Therefore, provided the case that pharmacological inhibitors of Fas are developed in the future to facilitate lithium- of more selective GSK-3 inhibitor-based therapies, it is possible that just a partial attenuation of Fas-dependent signaling might sufficient to preclude the effect of GSK-3 inhibitors on apoptosis induction. However, we should also keep in mind the potential drawbacks of prospective Fas inhibiting therapies as Fas signaling is required for many aspects of brain physiology such as neural progenitor survival [51].

An open question remains regarding the results reported here as whether the apoptosis observed in Tet/DN-GSK-3 mice and that disappears in the absence of fully functional Fas receptors is required for the motor phenotype that also gets normalized in a Fas deficient background. In fact, despite higher than in wild type mice, apoptotic rate in Tet/DN-GSK-3 mice is still low and does not produce a visible atrophy of affected structures. Alternatively, the effect in motor coordination could be caused not by the loss of a limited number of neurons in the circuit but by an alteration in the physiology of the global brain structure or circuit. In fact, our group has previously demonstrated that in a mouse model of striatal degeneration (HD94 mice) alterations in motor coordination occur in the absence of striatal cell loss, presumably by dysfunction of striatal neurons [52]. It is therefore possible that Fas signaling may also affect physiology of healthy neuronal circuits [53,54,55]. Thus an excessive Fas-FasL signaling could result in apoptosis of a limited number of neurons and in a more widespread dysregulation of neuronal physiology thus contributing to the behavioral consequences induced by GSK-3 inhibition.

In summary, here have genetically proven that neuronal apoptosis and motor deficits caused by sustained GSK-3 inhibition...
are Fas dependent. This might have important implications to enable combined therapies that could facilitate the clinical use of lithium and or more selective GSK-3 inhibitors not only for bipolar disorder but also for other diseases in which excess GSK-3 activity is believed to contribute to pathogenesis.

**Supporting Information**

**Figure S1** All genotypes show similar general locomotor behavior. Analysis of several parameters in open field test. Analysis of inactivity time (A), horizontal activity (B), vertical activity (C), jump time (D), stereotypic movements (E) or average velocity (F) was performed and no differences among genotypes were found. Statistical analysis was performed applying a one-way-ANOVA test except for jump time for that a Kruskal-Wallis test was applied. (TIF)

**References**

1. Doehle BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Biol 161: 1173–1186.
2. Frame S, Cohen P (2001) GSK3 acts in the endosome: more than 20 years after its discovery. Biochem J 359: 1–16.
3. Grimes CA, Joep RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391–426.
4. Hur EM, Zhou QX (2010) GSK3 functioning in neural development. Nat Rev Neurosci 11: 559–571.
5. Joep RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29: 95–102.
6. Hooger C, Markevich V, Plattner F, Killick R, Schofeld E, et al. (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation.
7. Peineau S, Taghibiglou C, Bradley C, Wong TP, Liu L, et al. (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53: 703–717.
8. Gwinn TD, Pechini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 7: 1399–1409.
9. Joep RS, Robl MS (2006) Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets 7: 1421–1434.
10. Kato T (2008) Molecular neurobiology of bipolar disorder: a disease of ‘mood-stabilizing neurona’? Trends Neurosci 31: 495–503.
11. Enamias EM, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36: 131–137.
12. Hooger C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer’s disease. J Neurochem 104: 1433–1439.
13. Kremer A, Louis JV, Jaworski T, Van Leuven F (2011) GSK3 and Alzheimer’s disease-modifying drugs.urr Drug Targets 13: 391–403.
14. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002) Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntingtin CAG expansion. J Biol Chem 277: 33789–33796.
15. Chin CT, Liu G, Leeds P, Chuang DM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington’s disease. Neuropsychopharmacology 36: 2406–2421.
16. Savaiedra A, Garcia-Martin JM, Xiffo X, Giralt A, Torres-Peraza IF, et al. (2010) PH domain leucine-rich repeat protein phosphatase 1 contributes to the maintenance of the Fas/FRNK pro-survival pathway in Huntington’s disease striatum. Cell Death Differ 17: 324–333.
17. Heumker EJ, Doeben BB (2006) Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 7: 1433–1441.
18. Manousakis AS, Woodgett JR (2002) Role of glycogen synthase kinase-3 in cancer; regulation by Wnt and other signaling pathways. Adv Cancer Res 84: 203–229.
19. Cohen P, Goedert M (2004) GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3: 479–487.
20. Meijer L, Fajadet M, Greengard P (2004) Pharmacological inhibitors of glycogen synthase kinase-3 (GSK3). Trends Pharmacol Sci 25: 471–480.
21. Gould TD, Einat H, Bhau R, Manji HK (2004) AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol 7: 387–390.
22. Scamboli V, Raul L, Woodgett JR (1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6: 1664–1668.
23. Klein PS, Melton DA (1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 4455–4459.
24. Gomez-Sintes R, Lucas JJ (2010) NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest 120: 2432–2445.
25. Macrìthie KAN, Young AH (2004) Adverse syndromes associated with lithium. In: Hadidi P, Durman S, Deakin B, editors. Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. Oxford University Press: 89–109.
26. Horlick KP, Luo J, Rubie EA, Tao MS, Jin O, et al. (2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406: 86–90.
27. Gomez-Sintes R, Fernandez F, Bortollozzi A, Ariaga F, Avila J, et al. (2007) Neurotrophic and trophic motor deficit in dominant-negative GSK-3 conditional transgenic mice. Emb J 26: 2743–2754.
28. Beurel E, Joep RS (2006) The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathway. Prog Neurobiol 79: 173–199.
29. Bevarti R, Vanhaesebroek B, Sufis P, Van Roy F, Fiers W (1989) Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. Proc Natl Acad Sci U S A 86: 9494–9498.
30. Song L, Zhou T, Joep RS (2004) Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC Neurosci 5: 20.
31. Phiel CJ, Klein PS (2003) Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 41: 789–813.
32. Paxinos G, Franklin KB (2011) The mouse brain in stereotaxic coordinates: Academic Press.
33. Hampton TG, Stasko MR, Kale A, Amendt I, Costa AC (2004) Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol Behav 82: 381–389.
34. Matsura K, Kabuo H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the movement disorder caused by striatal dopamine depletion. J Neurosci Methods 75: 145–148.
35. Cohen PL, Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and polyphorbic disease. Annu Rev Immunol 9: 243–269.
36. Bloksma N, de Bakker JM, van Rooijen HJ, Punt P, Seinen W, et al. (1994) Long-term treatment with 5,5-diphenylhydantoin reduces lymphadenopathy and anti-ssDNA autoantibodies in C57BL/6-lpr/lpr mice. Int J Immunopharmacol 16: 261–268.
37. Baldessarini RJ (2002) Treatment research in bipolar disorder: issues and recommendations. CNS Drugs 16: 721–729.
38. Young AH, Newham JJ (2006) Lithium in maintenance therapy for bipolar disorder. J Psychopharmacol 20: 17–22.
39. Forezza OV, Diniz MS, Radanovic M, Santos FS, Falib LL, et al. (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 198: 351–356.
40. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, et al. (2008) A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry 23: 704–711.
41. Medina M, Castro A (2008) Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic.Curr Opin Drug Discov Devel 11: 533–543.
42. Hu S, Begum AN, Jones MR, Oh MS, Beech WK, et al. (2009) GSK3 inhibitors show benefits in an Alzheimer’s disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33: 193–206.
43. Ethell DW, Kinloch R, Green DR (2002) Metalloproteinase shedding of Fas and Fas ligand regulates beta-amyloid neurotoxicity. Current biology : CB 12: 1595–1600.
44. Martinez M, Fernandez-Vivasos E, Frank A, De la Fuente M, Hernanz A (2008) Increased cerebrospinal fluid tau (Apo-E) levels in Alzheimer’s disease. Relationship with IL-6 concentrations. Brain research 869: 216–219.
45. Su JH, Anderson AJ, Gribbs DH, Tu C, Tong L, et al. (2003) Fas and Fas ligand are associated with neutritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiology of disease 12: 182–193.
46. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, et al. (2006) Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 290: 2302–2303.
47. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, et al. (2000) Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 290: 2304–2305.
48. Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, et al. (2000) Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer’s disease: finding of a positive association for a polymorphism in the TNFRSF6 gene. Human genetics 107: 391–396.
49. Erten-Lyons D, Jacobson A, Kramer P, Grupe A, Kaye J (2010) The FAS gene, brain volume, and disease progression in Alzheimer’s disease. Alzheimer’s & dementia : the journal of the Alzheimer’s Association 6: 118–124.
50. Sun M, Song L, Li Y, Zhou T, Jope RS (2008) Identification of an antiapoptotic protein complex at death receptors. Cell Death Differ 15: 1887–1900.
51. Knight JC, Scharf EL, Mao-Draayer Y (2010) Fas activation increases neural progenitor cell survival. J Neurosci Res 88: 746–757.
52. Diaz-Hernandez M, Torres-Peraza J, Salvatori-Abarca A, Moran MA, Gomez-Ramos P, et al. (2005) Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington’s disease. J Neurosci 25: 9773–9781.
53. Maelfait J, Beyaert R (2008) Non-apoptotic functions of caspase-8. Biochem Pharmacol 76: 1365–1373.
54. Reich A, Spering C, Schulz JB (2008) Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity? Trends Neurosci 31: 478–486.
55. Tourneur L, Chiocchia G (2010) FADD: a regulator of life and death. Trends Immunol 31: 260–269.